<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746562</url>
  </required_header>
  <id_info>
    <org_study_id>1600-1116</org_study_id>
    <nct_id>NCT02746562</nct_id>
  </id_info>
  <brief_title>Study Comparing Outcomes Between Conventional IVF and a &quot;Freeze-all&quot;-Strategy in Assisted Reproductive Technology</brief_title>
  <official_title>A Multicentre Randomized Controlled Trial of a &quot;Freeze All and Transfer Later&quot; Versus a Conventional &quot;Fresh Embryo Transfer&quot; Strategy for Assisted Reproductive Technology (ART) in Women With a Regular Menstrual Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anja Bisgaard Pinborg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holbaek Sygehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional Hospital Skive</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare conventional fresh embryo transfer with a &quot;freeze all
      and transfer later strategy&quot; in assisted reproductive technology in terms of ongoing
      pregnancy rates, live birth rates as well as perinatal outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicentre randomized controlled double-blinded trial with the purpose to
      investigate if pregnancy- and live birth rates can be improved by a &quot;freeze all and transfer
      later&quot;-strategy with transfer of the best quality, frozen, thawed embryo in a subsequent
      natural cycle compared with conventional fresh embryo transfer with transfer of the embryo in
      the stimulated cycle.

      In total 5 clinics in Denmark and Sweden will be participating in the recruitment of patients
      for the study.

      The patients will be screened and randomized computerized on cycle day 2 or 3 and allocated
      to one of the two study arms:

      I: hCG (human chorion gonadotrophin) arm with traditional hCG triggering and fresh blastocyst
      transfer II: GnRH (gonadotropin-releasing hormone)- agonist triggering arm with blastocyst
      cryopreservation and subsequent transfer in a subsequent natural cycle.

      The randomization will be done after the decision of gonadotrophin (rFSH/hMG) starting dose,
      and both doctor and patient will be blinded to the randomization until the day of hCG/agonist
      trigger. Both groups will be stimulated in a short GnRH antagonist protocol. The ovarian
      stimulation The gonadotrophin stimulation is performed according to the general standards in
      each of the clinics and can be altered according to the ovarian response with a maximum of
      300 IU.

      Blood samples are collected at baseline before the first gonadotrophin injection and at day
      of hCG injection and further blood samples in the luteal phase will be collected for a small
      subgroup of patients. All blood samples will be kept at the Biobank for the study at Hvidovre
      Hospital.

      Women in both arms will furthermore be requested to fill out a physical discomfort and a
      quality of life questionnaire at two different visits. Additionally the men will be asked to
      fill out quality of life questionnaires.

      Comprehensive sonography will be performed at the start of ovulation with details on each
      ovary. Ultrasound examination is performed on cycle day 2-3, at stimulation day 6 and
      thereafter every 2-3 days until ovulation is inducted.

      On the day of oocyte retrieval the randomization is unblinded. The oocytes are fertilized by
      either IVF or ICSI and cultured individually according to the normal procedures in the
      clinics.

      If the patient is allocated to the &quot;Fresh embryo transfer&quot;-group the best quality blastocyst
      will be transferred on day five after oocyte pick-up, if a blastocyst is developed. Surplus
      good quality blastocysts are vitrified on day five or six.

      For patients in the &quot;Freeze all&quot; group all embryos of good quality are vitrified at the
      blastocyst stage day 5 in the stimulated cycle according to the criteria for freezing
      blastocysts in each clinic. The highest quality embryo is selected and marked and will be the
      first one to be thawed after at least one mentrual cycle that is considered as a wash out
      period. Embryo transfer is performed 6-7 days after hCG injection in the blastocyst transfer
      cycle in this group.

      A serum beta-hCG test is performed 11 days after blastocyst transfer, and clinical pregnancy
      is confirmed by transvaginal ultrasound 3 to 4 weeks after a positive serum-hCG test.

      A follow-up of all pregnancies will be performed within three months after delivery or
      termination of pregnancy on predefined information sheets. All pregnancies resulting from
      blastocysts retrieved and thawed according to this study protocol will be followed from study
      inclusion and one year onwards.

      All data will be collected in a single database and all participants will be anonymized by
      way of an identificationcode. The biobank will be closed and all samples destroyed after 5
      years of the conclusion of the study at the latest.

      The study is a superiority study with 424 (212 in each arm) patients required to have an 80 %
      chance of detecting, as significant at the 5 % level, a decrease in the primary outcome
      measure from 30 % in the control group to 43 % in the experimental group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rates</measure>
    <time_frame>Two years</time_frame>
    <description>Outcome measured per transfer of the first blastocyst, per oocyte pick-up, per start of ovarian stimulation and per randomized patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Live birth rates</measure>
    <time_frame>Two years</time_frame>
    <description>Outcome measured after the first blastocyst transfer calculated per randomized patient, per started ovarian stimulation, per oocyte pick-up and per transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative live birth rates</measure>
    <time_frame>Two years</time_frame>
    <description>Measured after one stimulated cycle with oocyte retrieval and after use of all frozen blastocysts or after at least 1 year of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cycles with no embryo transfer</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-pregnancy</measure>
    <time_frame>Two years</time_frame>
    <description>From start of ovarian stimulation to positive hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-delivery</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low birth weight</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small-for-gestational age (SGA)</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Large-for-gestational age (LGA)</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal mortality</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preeclampsia</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental rupture</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive hCG 11 days post embryo transfer</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriages, biochemical pregnancies, ectopic pregnancies</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life for female and partner</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">424</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Freeze all</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfer of a frozen, thawed blastocyst in a subsequent natural menstrual cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fresh embryo transfer</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Freeze all</intervention_name>
    <description>Freezing of all blastocyst stage embryos with thawing and transfer in a subsequent natural cycle</description>
    <arm_group_label>Freeze all</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AMH (Anti-MÃ¼llerian hormone) &gt; 6.28 pmol/L (Roche Elecsys assay)

          -  Female age 18 years to less than 40 years

          -  1, 2 or 3 IVF/ICSI cycle with oocyte aspiration

          -  Regular menstrual cycle between 24 and 35 days

          -  BMI between 18 and 35

          -  Two ovaries

          -  Can and will sign informed consent

        Exclusion Criteria:

          -  Women who do not fulfil the inclusion criteria

          -  Endometriosis stage III to IV

          -  Ovarian cysts with diameter &gt; 30 mm at day of start of stimulation

          -  Submucosal fibroids

          -  Women with severe co-morbidity (IDDM, NIDDM, gastrointestinal, cardiovascular,
             pulmonary, liver or kidney disease)

          -  Dysregulation of thyroid disease

          -  Not danish or English speaking women

          -  Contraindications or allergies to use of Gonadotrophins or GnRH antagonists

          -  TESA (testicular sperm aspiration)

          -  OD (oocyte donation)

          -  Previous inclusion in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anja Bisgaard Pinborg, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Fertility Clinic, Obstetrical and Gynecological department, Hvidovre Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sacha Stormlund, MD</last_name>
    <email>sacha.stormlund.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anja Bisgaard Pinborg, MD, DMSc</last_name>
    <phone>+45 38 62 26 56</phone>
    <email>anja.bisgaard.pinborg@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sacha Stormlund, MD</last_name>
      <email>sacha.stormlund.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Hvidovre</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sacha Stormlund, MD</last_name>
      <email>sacha.stormlund.01@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Anja Pinborg, MD, DMSc</last_name>
      <email>anja.bisgaard.pinborg@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Anja Bisgaard Pinborg</investigator_full_name>
    <investigator_title>Professor, MD, DMSc</investigator_title>
  </responsible_party>
  <keyword>Assisted reproduction</keyword>
  <keyword>In vitro fertilisation</keyword>
  <keyword>Frozen embryo transfer (FER)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

